Kronik oral antikoagülan kullanımının robotik radikal prostatektomi sonuçlarına etkisi
Amaç: Kardiyovasküler hastalıklar nedeniyle kronik oral antikoagulan KOA kullanımının robotik radikal prostatektomi sonuçlarına etkisini araştırmak.Materials and Methods: Kliniğimizde 2008-2012 yılları arasında prostat kanseri tanısıyla robotik radikal prostatektomi uygulanan 200 hasta çalışmaya alındı. Birinci grupta kronik oral antikoagulan kullanan hastalara operasyondan bir hafta önce oral antikoagulan tedavi kesilerek düşük molekül ağırlıklı heparin DMAH başlandı ve ameliyat sonrası bir hafta devam edildi. İkinci grup, KOA kullanım öyküsü bulunmayan hastalar olup, ameliyat öncesi bir gün ve mobilizasyona kadar geçen süre boyunca düşük molekül ağırlıklı heparin subkutan profilaktik olarak verildi. Her iki grup operasyon süresi, ortalama kan kaybı, transfüzyon ihtiyacı, dren çekilme süresi, komplikasyon oranları ve hastanede kalış süreleri açısından karşılaştırıldı.Bulgular: Çalışmaya dahil edilen hastaların 24’ü oral antikoagulan kullanıyor idi. Kronik oral antikoagulan kullanan hastaların ortalama operasyon süresi 212,4 dakika iken kullanmayan grupta 212,7 dakika olarak saptandı p=0,86 . Tahmini kan kaybı grup 1 için 205 ml, grup 2 için 223 ml idi p=0,66 . Dren çekilmesi sırasıyla grup 1 ve grup 2 için 2,6 gün ve 2,2 gündü p=0,08 . Hastanede kalış süresi grup 1 için 3,8 gün grup 2 için 3,2 gün olarak hesaplandı p=0,09 . Her iki grubun total komplikasyon oranları %16 olarak gerçekleşti. Bununla birlikte minör ve majör komplikasyon oranları arasında da istatistiksel fark izlenmedi.Sonuç: Robotik radikal prostatektomi kronik oral antikoagulan kullanan cerrahi açıdan riskli hastalarda güvenle uygulanabilir
The impact of chronic oral anticoagulant therapy on robotic radical prostatectomy outcomes
Introduction: Patients undergoing robotic radical prostatectomy RARP who require chronic anticoagulant therapy due to cardiovascular conditions were evaluated for surgical outcomes. Materıal and Methods: In this study, 200 patients who underwent robotic radical prostatectomy with a diagnosis of prostate cancer between 2008 and 2012, were analyzed. In the first group, low molecular weight heparin LMWH was begun to be given to the patients by interrupting their use of oral anticoagulant therapy a week earlier than the surgery. The use of low molecular weight heparin was maintained about a week more after the surgery. The second group included patients who have no history of chronic use of oral anticoagulants therapy. To these patients, low molecular weight heparin as prophylactic was used subcutaneously a day before the surgery and continued until the mobilization. Operative time, blood loss, drain removal time, complication rates, length of hospital stay were compared between two groups.Results: In this study, 24 patients were using oral anticoagulant therapy. Mean operative time was 212,4 min in group 1 and 212,7 min in group 2 p=0.86 . Estimated blood loss was 205 ml and 223 ml in group 1 and 2, respectively p=0.66 . The drain was removed after 2.6 days in group 1 and 2.2 days in group 2. p=0.08 . The length of stay was a mean of 3.8 and 3.2 days in group 1 and 2 respectively p=0.09 . Total complication rate of both groups were 16%. In addition, no statistical difference was observed between minor and major complication rates. Conclusion: Robotic radical prostatectomy can be safely performed in patients who are at the risk of surgery and have been using chronic oral anticoagulant therapy
___
- Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long term biochemical disease free and cancer specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. UrolClin North Am 2001;28:555-565.
- Roehl KA, Han M, Ramos CG, Antenor JA, Catalona WJ. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive pati- ents: long term results. J Urol 2004;172:910-914.
- Dotan ZA, Mor Y, Leibovitch I, et al. The efficacy and safety of perioperative low molecular weight heparin substitution in patients on chronic oral anticoagulant therapy undergo- ing transurethral prostatectomy for bladder outlet obstruc- tion. J Urol 2002;168:610-614.
- Burger W, Chemnitius JM, Kneissl GD, Rücker G. Low dose aspirin for secondary cardiovascular prevention cardiovas- cular risks after its perioperative with drawal versus blee- ding risks with its continuation review and meta-analysis. J InternMed 2005; 257:399–414.
- Guillonneau B, Vallancien G. Laparoscopic radical prosta- tectomy: The Montsouris experience. J Urol 2000; 163: 418- 22
- Fareed J, Hoppensteadt DA, Bick RL. An update on hepa- rins at the begining of the new millenium. Semin Thromb Hemost 2000;26:5-21.
- Hoffman M, Monroe DM 3rd. A cell-based model of he- mostasis. Tromb Haemost 2001;85:958-65.
- Spandorfer J. The management of anticoagulation before and after procedures. MedClin North Am 2001;85:1109- 1116.
- Parr NJ, Loh CS, Desmond AD. Transurethral resection of the prostate and bladder tumour without with drawal of warfarin therapy. Br J Urol 1989;64:623-625.
- Ruszat R, Wyler S, Forster T, et al. Safety and effectiveness of photoselective vaporization of theprostate PVP in patients on ongoing oral anticoagulation. EurUrol 2007;51:1031- 1041.
- Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE. Photo- selective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 2005;19: 1196–8.
- Varkarakis IM, Rais-Bahrami S, Allaf ME, et al. Laparosco- pic renal-adrenal surgery in patients on oral anticoagulant- therapy. J Urol 2005;174:1020-1023.
- Kefer JC, Desai MM, Fergany A, Novick AC, Gill IS. Out- comes of Partial Nephrectomy in Patients on Chronic Oral Anticoagulant Therapy. J Urol 2008;180:2370-2374.
- Boczko J, Erturk E, Golijanin D, et al. Impact of prostate size in robot-assisted radical prostatectomy. J Endourol 2007;21:184-8.
- Krane LS, Laungani R, Satyanarayana R, et al. Robotic As- sisted Radical Prostatectomy in Patients Receiving Chronic Anticoagulation Therapy: Role of Perioperative Bridging. Urology 2008;72:1351-1355.